Suppliers and packagers for generic pharmaceutical drug: TRIFLURIDINE

TRIFLURIDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	TRIFLURIDINE	trifluridine	SOLUTION/DROPS;OPHTHALMIC	074311	ANDA	Sandoz Inc	61314-044-75	1 BOTTLE, PLASTIC in 1 CARTON (61314-044-75) / 7.5 mL in 1 BOTTLE, PLASTIC	2001-05-14

Trifluridine Suppliers and Patent Landscape

Last updated: February 19, 2026

Trifluridine, a nucleoside analog with antiviral properties, is primarily utilized in ophthalmic formulations for treating herpetic keratitis. Its pharmaceutical application is centered on the active pharmaceutical ingredient (API) itself and its incorporation into finished dosage forms. This analysis details key suppliers of trifluridine API and examines the patent landscape governing its production and application.

Who are the Primary Manufacturers of Trifluridine API?

Several entities globally produce trifluridine API. Production often involves complex synthesis pathways, necessitating specialized chemical manufacturing capabilities.

• Japanese Chemical Manufacturers: Japan has historically been a significant producer of nucleoside analogs, including trifluridine. Companies such as Taiyo Pharmaceutical Industry Co., Ltd. have been involved in its production. These manufacturers typically operate under strict Good Manufacturing Practices (GMP) regulations.
• Chinese Pharmaceutical Chemical Suppliers: A number of Chinese chemical companies are listed as suppliers of trifluridine API. These include entities like Hubei Jusheng Technology Co., Ltd. and Shanghai Syn-Tech Co., Ltd. These suppliers often cater to the global generic pharmaceutical market. Their production scales can vary, and sourcing from these suppliers requires rigorous quality control and due diligence regarding regulatory compliance.
• Indian Pharmaceutical Ingredient Manufacturers: India also hosts suppliers of trifluridine. While specific publicly listed primary manufacturers dedicated solely to trifluridine are less prominent than in other regions, many custom synthesis and generic API producers in India may offer trifluridine. Verification of their GMP certification and regulatory filings is crucial.

The supply chain for trifluridine API is subject to geographical concentration, with Asia, particularly China and Japan, playing a dominant role. Reliability of supply, quality assurance, and adherence to international regulatory standards (e.g., FDA, EMA) are critical selection criteria for pharmaceutical companies.

What is the Global Patent Landscape for Trifluridine?

The patent landscape for trifluridine is characterized by patents covering its synthesis, formulations, and therapeutic uses. While the core molecule itself is long-established, innovation continues in these areas.

Key Patent Categories:

1. Synthesis Processes: Patents often claim novel or improved methods for synthesizing trifluridine. These improvements can relate to yield, purity, cost-effectiveness, or environmental impact. Older patents covering foundational synthesis routes have likely expired, but newer variations and optimized processes may still be under patent protection.
2. Formulations: Pharmaceutical formulations of trifluridine, particularly ophthalmic solutions and ointments, are subject to patent protection. This includes claims on specific excipients, stabilization methods, delivery systems, and combinations with other active ingredients. The goal is often to improve bioavailability, patient compliance, or shelf life.
3. Therapeutic Uses and Methods of Treatment: While trifluridine is established for herpetic keratitis, new therapeutic applications or refined methods of treatment can be patented. This might include its use in combination therapies or for treating specific patient subpopulations.
4. Polymorphs and Salts: The identification and patenting of specific crystalline forms (polymorphs) or salts of trifluridine can impact its physicochemical properties, such as solubility and stability, and are therefore patentable subject matter.

Notable Patent Holders and Trends:

Historically, companies that developed and commercialized branded trifluridine products have held significant patents. For instance, Santen Pharmaceutical Co., Ltd., known for its ophthalmic products, has been a key player. Patents related to their Viroptic® formulation or similar products would have been critical.

• Generic Competition and Patent Expiry: As the patents on original trifluridine formulations and synthesis methods expire, generic manufacturers gain the opportunity to enter the market. This has led to a wave of patent challenges and the filing of Paragraph IV certifications in the United States, indicating that a generic applicant believes existing patents are invalid or will not be infringed by their product.
• Ongoing Innovation in Ophthalmic Delivery: Current patent filings often focus on enhancing the delivery of trifluridine to the eye. This includes novel excipient combinations that prolong corneal residence time, improve penetration, or reduce the frequency of administration. For example, patents might cover nanoparticle formulations or specialized mucoadhesive systems.
• Combination Therapies: Research and patent activity may also explore the synergistic effects of trifluridine when combined with other antiviral agents or therapeutic compounds for ophthalmic conditions.

Example Patent Scope: A patent might claim "An ophthalmic suspension comprising trifluridine, a non-ionic surfactant, and a buffering agent, wherein the pH of the suspension is between 6.5 and 7.5." Such a claim defines a specific composition and its characteristics.

The expiration of key patents can lead to increased competition and price reductions for trifluridine-based ophthalmic treatments. Companies seeking to enter or expand in this market must conduct thorough freedom-to-operate analyses to navigate existing patent rights and identify opportunities for new intellectual property.

How Does Regulatory Status Impact Trifluridine Supply and Patenting?

The regulatory status of trifluridine, particularly its approval by major health authorities, is intrinsically linked to its supply and patent landscape.

Regulatory Approvals:

• United States (FDA): Trifluridine is approved by the Food and Drug Administration (FDA) for the topical treatment of epithelial herpes simplex keratitis. Approved products, such as Viroptic®, have undergone rigorous clinical trials to demonstrate safety and efficacy. The FDA’s Orange Book lists approved drugs and their patent and exclusivity information, providing a critical resource for generic manufacturers.
• European Union (EMA): Similar approvals exist within the European Union, often through national regulatory bodies or the EMA centralized procedure.
• Other Jurisdictions: Approvals in other major markets like Japan and Canada are also essential for global commercialization.

Impact on Supply:

• GMP Compliance: API suppliers must adhere to Good Manufacturing Practices (GMP) as defined by regulatory agencies such as the FDA and EMA. Facilities are subject to inspection, and product quality must meet stringent specifications. Non-compliance can lead to import alerts, product recalls, and disruption of supply.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies referencing these DMFs in their marketing applications rely on their adequacy and currency.
• Supply Chain Scrutiny: Regulatory bodies increasingly scrutinize the entire pharmaceutical supply chain. This includes the sourcing of raw materials, the manufacturing of the API, and the formulation of the finished drug product.

Impact on Patenting:

• Patent Term Extension (PTE): In many jurisdictions, the patent term for a drug product can be extended to compensate for the time lost during the regulatory review process. This can prolong the market exclusivity for innovative trifluridine formulations or synthesis methods.
• Data Exclusivity: Regulatory agencies grant periods of data exclusivity upon approval of a new drug application (NDA). During this period, generic manufacturers cannot rely on the innovator's clinical trial data to support their own applications, even if the relevant patents have expired.
• Patent Challenges: The expiration of patents, coupled with the availability of generic alternatives, often triggers patent litigation. Generic companies may challenge the validity of remaining patents or argue that their products do not infringe. Regulatory filings, such as those made with the FDA, often become central to these legal disputes.

The interplay between regulatory approvals, patent protection, and supply chain integrity forms a complex ecosystem. Companies seeking to manufacture or market trifluridine products must navigate these elements meticulously to ensure compliance and market access.

What are the Key Chemical Specifications for Trifluridine API?

The quality and consistency of trifluridine API are paramount for the safety and efficacy of the final drug product. Key chemical specifications are defined by pharmacopoeias and internal quality control standards of manufacturers.

Pharmacopoeial Standards:

• United States Pharmacopeia (USP): The USP monograph for Trifluridine provides specific tests and acceptance criteria. These typically include:
  • Assay: Not less than 98.0% and not more than 102.0% of trifluridine, calculated on the dried basis. This ensures the potency of the API.
  • Identification: Tests to confirm the identity of trifluridine, often using infrared spectroscopy (IR) and chromatographic retention times.
  • Related Substances/Impurities: Limits on specified and unspecified impurities. These include process-related impurities, degradation products, and residual solvents. chromatographic methods like High-Performance Liquid Chromatography (HPLC) are used. Examples of potential impurities might include starting materials or by-products from the synthesis.
  • Loss on Drying: A limit on the amount of volatile matter (primarily water) that can be present.
  • Residue on Ignition: A limit on the amount of inorganic residue remaining after ignition, indicating the absence of inorganic impurities.
  • Specific Rotation: A measure of the optical activity of the compound.
• European Pharmacopoeia (Ph. Eur.): The Ph. Eur. monograph for Trifluridine also sets standards, which are often harmonized with USP but may have minor differences in methodology or limits.

Manufacturer-Specific Standards:

Beyond pharmacopoeial requirements, API manufacturers establish their own internal specifications to ensure lot-to-lot consistency and to meet the specific requirements of their pharmaceutical clients. These may include:

• Particle Size Distribution: For solid APIs, particle size can significantly influence dissolution rates and processability during drug product manufacturing.
• Polymorphic Form: Control over the crystalline form of trifluridine is crucial, as different polymorphs can exhibit different solubilities and stabilities. Techniques like X-ray Powder Diffraction (XRPD) are used for characterization.
• Heavy Metals: Strict limits on heavy metal contamination are enforced to prevent toxicity.
• Microbial Limits: For APIs used in sterile ophthalmic preparations, controls on microbial contamination are critical.

Example Specification: A USP specification for Related Substances might state that "any individual unspecified impurity should not exceed 0.10%," and "the total impurities should not exceed 1.0%."

Sourcing trifluridine API requires a thorough understanding of these specifications and verification that the chosen supplier can consistently meet them, supported by Certificates of Analysis (CoA) and audited quality systems.

What are the Primary Uses and Formulations of Trifluridine?

Trifluridine's primary pharmaceutical application is as an antiviral agent, specifically targeting herpes simplex viruses (HSV). Its clinical utility is predominantly in ophthalmology.

Key Indications:

• Herpetic Keratitis: Trifluridine is a first-line treatment for epithelial herpes simplex keratitis, a viral infection of the cornea caused by HSV. It is effective against both HSV-1 and HSV-2.
• Recurrent Corneal Epithelial Disease: It is also used in managing recurrent episodes of this corneal infection.

Principal Formulations:

Trifluridine is formulated almost exclusively for topical ophthalmic administration.

• Ophthalmic Solutions (Eye Drops): This is the most common formulation. These solutions are sterile preparations designed for direct instillation into the eye. They typically contain trifluridine at a concentration of 1% (10 mg/mL).
  • Composition: Ophthalmic solutions contain trifluridine as the active ingredient along with various excipients to ensure stability, isotonicity, pH buffering, and preservation. Common excipients include:
    • Buffering Agents: Such as sodium acetate or phosphate buffers to maintain a physiological pH (typically around 6.5-7.5) for ocular comfort and drug stability.
    • Tonicity Adjusters: Like sodium chloride or mannitol to make the solution isotonic with tear fluid, preventing irritation.
    • Preservatives: Benzalkonium chloride is a common preservative in multi-dose ophthalmic solutions to prevent microbial contamination after opening. However, preservative-free single-dose units are also utilized to minimize ocular surface toxicity.
    • Thickening Agents: Sometimes included to increase corneal contact time.
• Ophthalmic Ointments: While less common, trifluridine can also be formulated as an ophthalmic ointment for prolonged contact with the ocular surface, potentially offering extended therapeutic effect. These are typically sterile, petrolatum-based preparations.

Example Product: Viroptic® (trifluridine ophthalmic solution) 1% by Santen Pharmaceutical Co., Ltd. is a well-established brand name product.

The formulation development of trifluridine eye drops has focused on optimizing stability and ocular penetration while minimizing patient discomfort and potential side effects associated with preservatives or pH variations. Patents in this area often protect these specific formulation innovations.

Key Takeaways

Trifluridine API is primarily manufactured by chemical companies in Japan and China. The patent landscape is characterized by expired foundational synthesis patents and ongoing innovation in formulation and delivery systems, particularly for ophthalmic applications. Regulatory approvals from agencies like the FDA and EMA are critical for market access, influencing both supply chain compliance and patent term extensions. Key specifications for trifluridine API, outlined in pharmacopoeias like USP and Ph. Eur., focus on assay, impurity profiles, and physical characteristics. The principal use of trifluridine is in ophthalmic solutions for treating herpetic keratitis, with formulation patents protecting excipient combinations and delivery enhancements.

FAQs

1. Are there any novel therapeutic applications for trifluridine currently under development that are covered by recent patents? While the primary application remains herpetic keratitis, patent literature may reveal explorations into combination therapies for other viral infections or novel delivery methods for enhanced efficacy or reduced toxicity. Such developments are often detailed in patent filings rather than early-stage clinical trial announcements.

2. What are the typical lead times for sourcing trifluridine API from Asian suppliers, and what quality assurance measures are essential? Lead times can vary from 8-16 weeks, depending on production schedules and order volumes. Essential quality assurance measures include verifying GMP certification, reviewing recent audit reports, conducting site visits if possible, and thoroughly scrutinizing Certificates of Analysis (CoA) for compliance with pharmacopoeial and internal specifications.

3. How does the presence of preservatives like benzalkonium chloride in trifluridine ophthalmic solutions impact its patentability and commercialization? Preservatives are typically considered standard excipients. Patents related to preservative use would likely focus on novel preservative systems or methods to mitigate preservative-induced ocular surface toxicity, rather than the presence of common preservatives themselves. Commercialization considerations include patient tolerance and potential regulatory scrutiny of preservatives.

4. What are the key differences in quality standards for trifluridine API intended for the US market versus the European market? The primary difference lies in the specific pharmacopoeial standards referenced (USP for the US, Ph. Eur. for Europe) and potentially minor variations in testing methodologies or impurity limits. However, there is significant harmonization between these pharmacopoeias, and suppliers aiming for global markets typically adhere to both.

5. Can a company develop a generic trifluridine ophthalmic formulation if the patent for the active pharmaceutical ingredient itself has expired but patents for specific formulations are still active? No, a company cannot generally develop and market a generic formulation if a valid and unexpired patent covers that specific formulation, its composition, or its method of use. Generic companies must either wait for all relevant formulation patents to expire, successfully challenge those patents, or develop a non-infringing formulation.

Citations

[1] United States Pharmacopeia. (n.d.). Trifluridine. USP-NF. [2] European Pharmacopoeia. (n.d.). Trifluridine. Ph. Eur. [3] Santen Pharmaceutical Co., Ltd. (n.d.). Product Information for Viroptic®. Retrieved from company website. [4] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA website. [5] Hubei Jusheng Technology Co., Ltd. (n.d.). Trifluridine Product Information. Retrieved from company website/chemical supplier databases. [6] Shanghai Syn-Tech Co., Ltd. (n.d.). Trifluridine Product Information. Retrieved from company website/chemical supplier databases. [7] Taiyo Pharmaceutical Industry Co., Ltd. (n.d.). Company Information. Retrieved from company website.